RESULTS INTRODUCTION aim METHOD conclusions references

Slides:



Advertisements
Similar presentations
Program Number TO021 – 50 th ERA-EDTA Congress – May 21, Oral treatment with a novel first-in-class anti-fibrotic compound PBI-4050 reduces hepatic.
Advertisements

S_khalilzadeh. NAFLD and T2DM NAFLD is closely associated with features of the metabolic syndrome and is regarded as the hepatic manifestation of the.
LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC) and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL)
By Hussam A.S. Murad and Khaled A. Mahmoud Department of Pharmacology and Therapeutics Faculty of Medicine, Ain Shams University By Hussam A.S. Murad.
Oxidative Stress in Skeletal Muscle Diabetes This study was initiated to more rigorously examine insulin actions in the context of heightened state of.
EC917 Eva Gallardo, MD Medical Manager, Biocompatibles UK Drug Eluting Bead: Future Product Applications.
The FATZO mouse as a Translational Model for the Development of Drugs for Obesity, Metabolic Syndrome and Diabetes. PreClinOmics, Inc. 1.
Jun Yu,1,2 Joseph Jao-Yiu Sung,1,2 Henry Lik-Yuen Chan1,2
Date of download: 7/5/2016 From: Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus:
Volume 36, Issue 12, Pages (December 2016)
A promising target for NASH
Glutamic acid ameliorates estrogen deficiency–induced menopausal-like symptoms in ovariectomized mice  Na-Ra Han, Hee-Yun Kim, Woong Mo Yang, Hyun-Ja.
Volume 66, Issue 5, Pages (May 2017)
Fig. 1. Body growth and leptin responsivity in young CPO and CTR mice
Prof. Sayed H. Seif el-Din Theodor Bilharz Research Institute
BY: Asmaa Alastal. wafaa hanouna. Salma abu taha. .Sara shaban
Peter L. Lee, Yuefeng Tang, Huawei Li, David A. Guertin 
Prevention of Metabolic Endotoxemia With Pro- and Prebiotics
Volume 133, Issue 2, Pages (August 2007)
Serotonin Has a Key Role in Pathogenesis of Experimental Colitis
Clinical Nutrition Experimental
Volume 20, Issue 3, Pages (July 2017)
Athena Kalyvas, Samuel David  Neuron 
Volume 15, Issue 1, Pages (January 2012)
C-kit Inhibition by Imatinib Mesylate Attenuates Progenitor Cell Expansion and Inhibits Liver Tumor Formation in Mice  Belinda Knight, Janina E.E. Tirnitz–Parker,
An Albumin-Exendin-4 Conjugate Engages Central and Peripheral Circuits Regulating Murine Energy and Glucose Homeostasis  Laurie L. Baggio, Qingling Huang,
Mary Chatterjee, Kasturi Sarkar, Parames C. Sil  Pathophysiology 
Volume 131, Issue 4, Pages (October 2006)
Volume 128, Issue 5, Pages (May 2005)
Volume 8, Issue 4, Pages (October 2008)
Volume 137, Issue 4, Pages e5 (October 2009)
Volume 117, Issue 4, Pages (October 1999)
Volume 143, Issue 3, Pages (September 2012)
Galectin-1 suppresses experimental colitis in mice
Volume 115, Issue 1, Pages (July 1998)
High LDL levels lead to increased synovial inflammation and accelerated ectopic bone formation during experimental osteoarthritis  W. de Munter, M.H.
Frank J. Gonzalez, Changtao Jiang, Andrew D. Patterson 
Volume 155, Issue 2, Pages (August 2018)
Effects of Intravenous Immunoglobulins on Mice with Experimental Epidermolysis Bullosa Acquisita  Misa Hirose, Benjamin Tiburzy, Norito Ishii, Elena Pipi,
Fig. 1. NASH and fibrosis develop late in mice fed an HFD.
Volume 63, Issue 3, Pages (September 2015)
Therapeutic Benefit of Bortezomib on Acute Graft-versus-Host Disease Is Tissue Specific and Is Associated with Interleukin-6 Levels  Chien-Chun Steven.
Volume 8, Issue 4, Pages (August 2014)
Volume 140, Issue 2, Pages e4 (February 2011)
Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity  Zhang-Xu Liu, Sugantha Govindarajan,
Type 1 immunity drives metabolic disease but protects against NAFLD
Volume 18, Issue 5, Pages (November 2013)
Volume 126, Issue 3, Pages (March 2004)
Volume 16, Issue 1, Pages (July 2012)
Heat Shock Transcription Factor 1 Is a Key Determinant of HCC Development by Regulating Hepatic Steatosis and Metabolic Syndrome  Xiongjie Jin, Demetrius.
miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK
Molecular Therapy - Nucleic Acids
Volume 127, Issue 3, Pages (September 2004)
Volume 59, Issue 2, Pages (August 2013)
Volume 26, Issue 3, Pages (March 2018)
NASH animal models: Are we there yet?
Volume 22, Issue 2, Pages (August 2015)
Masanobu Ishii et al. BTS 2017;2:
Major classes of drugs to reduce lipids
A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis  Arun J. Sanyal, Pouneh S. Mofrad, Melissa.
Volume 21, Issue 3, Pages (March 2013)
Selonsertib in NASH: phase 2
NGM282 in NASH: 3 mg QD (phase 2)
Volume 22, Issue 2, Pages (August 2015)
NGM282, NAS and fibrosis in NASH: a phase 2 study
Systemic PPARγ Ligation Inhibits Allergic Immune Response in the Skin
Hepatic PPARγ deficiency impairs the SCFA-induced reduction in hepatic steatosis. Hepatic PPARγ deficiency impairs the SCFA-induced reduction in hepatic.
Adipose Fatty Acid Oxidation Is Required for Thermogenesis and Potentiates Oxidative Stress-Induced Inflammation  Jieun Lee, Jessica M. Ellis, Michael J.
Volume 18, Issue 3, Pages (January 2017)
A B Figure S1, Effect of CH diet consumption for six weeks on mice hepatic morphology. Representative histologic microphotographs of H&E stained liver.
Presentation transcript:

RESULTS INTRODUCTION aim METHOD conclusions references Mitochondrial Uncoupler HU6 Reduces Hepatic Oxidative Stress in the DIAMOND™ Mouse Model Thus Abrogating NASH Development. Francisco Portell 3, Stephen Eaton 3, Jameel Dennis 3, Rebecca Caffrey 1, Jonathon Marioneaux 1, Isaac Onyango 3, Omer Khan 3, Shaharyar Khan 3 and Arun Sanyal 2 1. Sanyal biotechnology LLC, Norfolk, VA, United States. 2. Virginia Commonwealth University, Richmond,VA, United States. 3. Gencia INTRODUCTION The Gencia mitochondrial uncoupler HU6 was evaluated for utility in treating NASH in a diet-induced animal model of metabolic syndrome and NASH (DIAMOND™ mice); development of NASH in this model is driven by insulin resistance, oxidative stress, inflammation, and leaky gut induced by Western Diet (WDSW). RESULTS Serum ALT, AST and ALP levels in the HD group were significantly lower than in the VC (P=0.001, 0.0004, and 0.0002, respectively) and PC (P=0.03, 0.01, and 0.00008, respectively) groups. In the HD group the significant reduction in ballooning (P=0.0000001), lobular inflammation and liver transaminotransferase levels is accompanied by a 72% reduction in MCP-1, 37% reduction in IP-10, 50% reduction in MCP-3 and a 43% reduction in MIP-2. Additionally, HU6-treated mice have a near 25% reduction in baseline oxidative damage to nucleic acids. Steatosis percentage and grade (P=0.001 and 0.01, respectively) were reduced in the HD group, which correlated with significantly lower body weights and liver weights compared to the VC and PC groups. Composite histology scores (NAS and SAF activity scores) were also significantly improved in the HD group compared to VC and PC groups. While all VC and PC mice progressed to NASH, HU6 at 5 mg/kg prevented NASH development in all but one mouse. Histology Scores Blood chemistry Vehicle Control Sirius Red Mouse ID 495 – 10X High Dose Sirius Red Mouse ID 619 – 10X Low Dose Sirius Red Mouse ID 619 – 10X Positive Control Sirius Red Mouse ID 574 – 10X Negative Control H&E Mouse ID 699 – 10X Negative Control Sirius Red Mouse ID 699 – 10 Vehicle Control H&E Mouse ID 495 – 10X High Dose H&E Mouse ID 619 – 10X Low Dose H&E Mouse ID 619 – 10X Positive Control H&E Mouse ID 574 – 10X MIP-2 MCP-3 MCP-1 IP-10 DNA/RNA Oxidative damage Chemokine/Cytokine aim The aim of this study was to investigate effects of HU6 on ROS formation and correlate these with disease progression. . METHOD Mice were grouped into 5 groups: vehicle control (VC), high dose HU6 (HD), 5 mg/kg), low dose HU6 (LD, 1 mg/kg), WDSW positive (PC) and NCNW negative (NC) natural history controls. Mice were raised for 12 weeks on diet, corresponding to a baseline NASH F0 in the WDSW groups. Treatment groups were then gavaged once daily with aqueous vehicle or drug in vehicle for 8 weeks. Serum and liver tissue were harvested, snap frozen and fixed, and LFTs, blood lipids and histology on FFPE section stained with H&E and Sirius Red was performed. DNA/RNA oxidative damage was measured via ELISA from representative liver samples. Key chemokines were also assayed from mouse livers utilizing Luminex Bead-based multiplex assays. conclusions With only eight week of dosing low levels of HU6, measures of oxidative stress and chemokines, correlating with decreases in ballooning, inflammation, and progression from simple steatosis to NASH, were significantly reduced. HU6 also produced significant reductions in body and liver weight, correlating with decreased hepatic steatosis. HU6 impacted multiple drivers of NASH in this study, thus supporting the rationale for further study of HU6’s therapeutic potential in NASH. Mansouri A, Gattolliat CH, Asselah T. Mitochondrial Dysfunction and Signaling in Chronic Liver Diseases. Gastroenterology Vol.155, pp 629-647. 2018 references CONTACT INFORMATION Rebecca Caffrey rebecca@sanyalbio.com Francisco Portell frportell@genciabiotech.com